1,692
Views
163
CrossRef citations to date
0
Altmetric
Perspective

The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety

Pages 305-310 | Published online: 29 Mar 2010

Bibliography

  • Ehrlich P. Chemotherapeutics: scientific principles, methods and results. Lancet 1913;182:445-51
  • Fischer E. Einfluss der configuration auf die wirkung der enzyme. Ber Dtsch Chem Ges 1894;27:2985-2993
  • Morrison JF, Walsh CT. The behavior and significance of slow-binding enzyme inhibitors. Adv Enzymol 1988;61:201-301
  • Swinney DC. Biochemical mechanisms of drug action: what does it take for success? Nature Rev Drug Discov 2004;3:27-41
  • Boehr DD, Nussinov R, Wright PE. The role of dynamic conformational ensembles in biomolecular recognition. Nature Chem Biol 2009;5:789-96
  • Copeland RA. Enzymes: a practical introduction to structure, mechanism and data analysis. Wiley, New York; 2000
  • Copeland RA. Evaluation of enzyme inhibitors in drug discovery: a guide for medicinal chemists and pharmacologists. Wiley, Hoboken, NJ, USA; 2005
  • Copeland RA, Pompliano DL, Meek TD. Drug-target residence time and its implications for lead optimization. Nature Rev Drug Discov 2006;5:730-9
  • Tummino PJ, Copeland RA. Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry 2008;47:5481-92
  • Vauquelin G, Van Liefde I. Slow antagonist dissociation and long-lasting in vivo receptor protection. Trends Pharmacol Sci 2006;27:355-9
  • Szczuka A, Wennerberg M, Packeu A, Vauquelin G. Molecular mechanisms for the persistent bronchodilatory effect of the beta2-adrenoceptor agonist salmeterol. Brit J Pharmacol 2009;158:183-94
  • Vauquelin G, Fierens F, Van Liefde I. Long-lasting angiotesin Type 1 receptor binding and protection by candesartan: comparison with other biphenyl-tetrazole sartans. J Hypertens 2006;24:S23-30
  • Zhang R, Monsma F. The importance of drug-target residence time. Current Opin Drug Discov Dev 2009;12:488-96
  • Weikl TR, von Deuster C. Selected-fit versus induced-fit protein binding: kinetic differences and mutational analysis. Proteins 2009;75:104-10
  • Ploeger BA, van der Graaf PH, Danhof M. Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling. Drug Metab Pharmacokinet 2009;24:3-15
  • Malany S, Hernandez LM, Smith WF, Analytical method for simultaneously measuring ex vivo drug receptor occupancy and dissociation rate: application to (R)-dimethindene occupancy of central histamine H1 receptors. J Receptors Signal Transduct 2009;29:84-93
  • Tillotson B, Coco J, Whitebread N, A novel pharmacodynamic assay to measure HSP90 target occupancy by the small molecule inhibitors IPI-504 and IPI-493 in tumors. American Association for Cancer Research Annual Meeting 2009; Abstract 1710
  • Lindström E, von Mentzer B, Påhlman I, Neurokinin 1 receptor antagonists: correlation between in vitro receptor interaction and in vivo efficacy. J Pharmacol Exp Ther 2007;322:1286-93
  • Lu H, England K, am Ende C, Slow-onset inhibition of the FabI enoyl reductase from Francisella tularensis: residence time and in vivo activity. ACS Chem Biol 2009;4:221-31
  • Dierynck I, De Wit M, Gustin E, Binding kinetics of darunavir to human immunodeficiency virus Type 1 protease explain the potent antiviral activity and high genetic barrier. J Virology 2007;81:13845-51
  • Perni RB, Almquist SJ, Byrn RA, Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 2006;50:899-909
  • Rajagopalan R, Misialek S, Stevens SK, Inhibition and binding kinetics of the hepatitis C virus NS3 protease inhibitor ITMN-191 reveal tight binding and slow dissociation behavior. Biochemistry 2009;48:2559-68
  • Lewandowicz A, Tyler P, Evans GB, Achieving the ultimate physiological goal in transition state analogue inhibitors for purine nucleoside phosphorylase. J Biol Chem 2003;278:31465-8
  • Bryant J, Post JM, Alexander S, Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (I): in vitro effects on platelets. Thrombosis Res 2008;122:523-32
  • Walker I, Newell H. Do molecularly targeted agents in oncology have reduced attrition rates? Nat Rev Drug Discov 2009;8:15-6
  • Cooper MA. Optical biosensors in drug discovery. Nature Rev Drug Discov 2002;1:515-28
  • Danielson UH. Integrating surface plasmon resonance biosensor-based interaction kinetic analysis into the lead discovery and optimization process. Future Med Chem 2009;1:1399-414
  • Yan K, Madden L, Choudhry AE, Biochemical characterization of the interactions of the novel pleuromutilin derivative retapamulin with bacterial ribosomes. Antimicrob Agents Chemother 2006;50:3875-81
  • Kohout TA, Reijmers S, Finn KJ, Trapping of a nonpeptide ligand by the extracellular domains of the gonadotropin-releasing hormone receptor results in insurmountable antagonism. Mol Pharmacol 2007;72:238-47
  • Gabrielsson J, Dolgos H, Gillberg P-G, Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations. Drug Discov Today 2009;14:358-72

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.